KYORIN Pharmaceutical Co.,Ltd. · TSE:4569

KYORIN Pharmaceutical Co.,Ltd — FY2022 Earnings Presentation

41 slides from KYORIN Pharmaceutical Co.,Ltd's earnings presentation, May 12, 2023

  1. Slide 1: Financial Results Ended March 2023

    Financial Results Ended March 2023 May 12 , 2023 KYORIN Pharmaceutical Co., Ltd. Representative Director, President and CEO Yutaka Ogihara

  2. Slide 2: Outline of Consolidated Financial Results

    Outline of Consolidated Financial Results Trends of mainstay products, generic product Consolidated Financial Forecast Status of R&D Pipeline Overview of the Long-term Vision “HOPE 100 –Stage 3–” New Long-term Vision “Vision 110”(FY2023-FY2032) and Medium-term Business Plan “Vision 110 –Stage 1–” (F

  3. Slide 3: Outline of Consolidated Financial Results

    Outline of Consolidated Financial Results 3

  4. Slide 4: Breakdown of Gain and Loss FY2022

    Breakdown of Gain and Loss FY2022 (Units: JPY billions) Year-on-year Vs forecast (announced on May 11, 2022) FY2021 FY2022 Change Change (%) Change Net Sales 105.5 113.3 +7.8 +7.3 +1.3 New drugs, etc. (Japan) 69.7 74.8 +5.1 +7.2 +0.3 New drugs (Overseas) 1.0 0.3 -0.7 -70.1 -0.4 Generic drugs 34.8 38

  5. Slide 5: Highlights of Business Performance (1/3) YoY: Net Sales

    Highlights of Business Performance (1/3) YoY: Net Sales (Units: JPY billions) [Net Sales 113.3] 120.0 113.3 105.5 New drugs, etc. (Japan): sales increased + 5.1 100.0 [Factors of increase] 38.2 ⚫ New drugs (Beova, Dezalex, Lasvic) grew 34.8 ⚫ Increase in sales of out-licensing product (Beova) 80.0 [

  6. Slide 6: Highlights of Business Performance (2/3) YoY: Operating Profit

    Highlights of Business Performance (2/ 3) YoY: Operating Profit (Units: JPY billions) 6 [Operation profit +0.1] 5.0 +0.7 5.1 Gross profit increased + 0.7 5 +2.0 Net sales + 7.8 -1.4 Cost of + 2 . 5 %pt 4 sales ratio Factor of New drugs (Beova, Dezalex etc) grew Increase Factor of NHI drug price revi

  7. Slide 7: Highlights of Business Performance (3/3) vs Forecast

    Highlights of Business Performance (3/3) vs Forecast (Units: JPY billions) Year-on-year vs forecast (announced on May 11, 2022) FY2021 FY2022 Change Change (%) Change Net Sales 105.5 113.3 + 7.8 + 7.3 + 1.3 New drugs, etc. (Japan) 69.7 74.8 + 5.1 + 7.2 + 0.3 New drugs (Overseas) 1.0 0.3 -0.7 -70.1 -

  8. Slide 8: FY2022 Main Product Sales Update

    FY2022 Main Product Sales Update (Units: JPY billions) Year-on-year vs Forecast FY2021 FY2022 (announced on May 11, 2022) Change Change (%) Change Beova (KYORIN) (β3 adrenergic receptor agonist overactive bladder therapeutics ) 8.6 12.9 +4.3 +49.8 -1.2 Lasvic (New quinolone synthetic antibacterial a

  9. Slide 9: Trends of Mainstay Products and Generic Drugs

    Trends of Mainstay Products and Generic Drugs 9

  10. Slide 10: Mainstay products: Beova (Therapeutic agent for OAB)

    [Mainstay products] Beova (Therapeutic agent for OAB) Anticholinergic agents β3 receptor antagonist others OAB market Beova(KYORIN) share Sales (Units: JPY billion) (Units: JPY billion) (%) 100 96.3 97.7 93.0 89.0 20 20 91.3 16.7 80 40.3 30.6 20.9 15 15 48.1 60 53.3 10.2 8.6 10 10 18.9 40 5.0 68.1 1

  11. Slide 11: Mainstay products: Lasvic (New quinolone antibacterial agent)

    [Mainstay products] Lasvic (New quinolone synthetic antibacterial agent) Oral antimicrobial market Lasvic share Sales (Units: JPY billions) (%) 120.0 12 3 80.0 8 2 105.6 3.2 96.2 4.0 40.0 63.3 4 2.5 2.9 1 1.9 1.8 0.9 62.3 60.5 1.1 0.9 0.0 0 0 19/3 20/3 21/3 22/3 23/3 20/3 21/3 22/3 23/3 24/3 Copyrig

  12. Slide 12: Mainstay products: Lyfnua (Cough treatment)

    [Mainstay products] Lyfnua (Cough treatment) The number of estimated patients Sales 1.5 Chronic chough patients RCC/UCC patients 2,500 K 400 K ~ 500 K 1.0 1.3 Definition of Refractory/Unexplained Chronic Cough 0.5 RCC/UCC 0.2 0.0 23/3 24/3 (Forecast) Status in FY2022 Refractory chronic Unexplained c

  13. Slide 13: Mainstay products: Desalex (Antiallergic Agent)

    [Mainstay products] Desalex (Antiallergic Agent) Antihistamine market Sales (Units: JPY billions) New drugs Long-listed and generic drugs Desalex share(%) (Units: JPY billions) 180.0 15.0 162.1 156.2 10 150.0 137.0 125.6 122.0 8 120.0 10.0 95.7 85.2 8.1 83.7 6 98.6 6.6 90.0 74.5 4.9 8.5 8.9 4 60.0 5

  14. Slide 14: Mainstay products: Flutiform (Anti-asthmatic)

    [Mainstay products] Flutiform(Anti-asthmatic) ICS/LABA market Flutiform share Sales (Units: JPY billions) (Units: %) (Units: JPY billions) 140.0 20 14 120.0 15.5 15.9 16.0 12 100.0 13.2 15 12.2 10 80.0 8 10 14.6 60.0 120.3 123.2 13.3 12.6 6 12.0 11.4 101.3 40.0 90.4 85.6 5 4 20.0 2 0.0 0 0 19/3 20/3

  15. Slide 15: Status of Generic Drugs

    Status of Generic Drugs Sales in GE Sales in AG (three products) among with the sales at left (Units: JPY billions) (Units: JPY billions) 40 20 30 15 20 10 38.2 36.6 18.7 34.8 16.6 31.0 32.2 15.4 14.8 14.3 10 5 0 0 20/3 21/3 22/3 23/3 24/3 20/3 21/3 22/3 23/3 24/3 (Forecast) (Forecast) Status in FY2

  16. Slide 16: Consolidated Financial Forecast FY2023

    Consolidated Financial Forecast FY2023 16

  17. Slide 17: Consolidated Financial Forecast

    Consolidated Financial Forecast FY2022 (Unit: JPY billion) Year-on-year FY2022 FY2023 Change Change (%) Net Sales 113.3 116.2 + 2.9 + 2.6 New drugs, etc. (Japan) 74.8 79.1 + 4.3 + 5.8 New drugs (Overseas) 0.3 0.4 + 0.1 + 29.6 Generic drugs 38.2 36.6 -1.6 -4.2 Cost of sales 63.1 - - - SG&A (R&D) 45.0

  18. Slide 18: Forecast of Mainstay Products Sales

    Forecast of Mainstay Products Sales (Unit: JPY billions) FY2023 Year-on-year FY2022 (Forecast) Change Change (%) Beova (KYORIN) (β3 adrenergic receptor agonist overactive bladder therapeutics ) 12.9 18.9 + 6.0 + 46.8 Lasvic (New quinolone synthetic antibacterial agent) 2.5 3.2 + 0.7 + 32.6 Lyfnua (S

  19. Slide 19: Shareholders Returns

    Shareholders Returns ● While maintaining the sound financial base, we aim to improve the capital Capital efficiency through growth investment and returns to shareholders Policy ● We will maintain stable dividends taking DOE (Dividend on Equity ratio) into account Dividend FY2023 FY2020 FY2021 FY2022

  20. Slide 20: Status of R&D Pipeline

    Kyorin ©) | Status of R&D Pipeline

  21. Slide 21: Status of R&D Pipeline in FY2022

    Status of R&D Pipeline in FY2022 Development code Ph1 Ph2 Ph3 Application Approval/Launch Respiratory KRP-R120 MRCT*1 (April 2021) MRCT ※1 Infections KRP-A218 (Completed Urology AKP-009*2 by Aska) KRP-114VP (August 2022) *1 MRCT: Multi-Regional Clinical Trials *2 Additional Ph1 study to confirm the

  22. Slide 22: Plan of R&D Pipeline in FY2023

    Plan of R&D Pipeline in FY2023 Development code Ph1 Ph2 Ph3 Application Approval/Launch Respiratory KRP-R120 MRCT*1 (April 2021) MRCT ※1 Infections KRP-A218 (Completed Urology AKP-009*2 by Aska) KRP-114VP (August 2022) *1 MRCT: Multi-Regional Clinical Trials *2 Ph1 study under preparation (ASKA) [Li

  23. Slide 23: Initiative toward Realization of the Long-term Vision HOPE 100

    Initiative toward Realization of the Long-term Vision “HOPE 100” 23

  24. Slide 24: Overview of Medium-Term Business Plan HOPE 100-Stage 3-

    Overview of Medium-Term Business Plan “HOPE 100-Stage 3-” Long-Term Vision [HOPE100] Statement The Kyorin Group will promote diversified healthcare business expansion and by 2023 be recognized both within and outside as a company that supports sound and healthy lifestyles. Stage 1 Stage 2 Stage 3 FY

  25. Slide 25: Realize growth trend by pursuing Kyorin's originality

    Overview of Medium-Term Business Plan “HOPE 100-Stage 3-” Statement Realize growth trend by pursuing Kyorin’s originality ● Shift to business based on the proposal of solutions and accelerate the growth of new drug groups Business ● Enhance pipeline to support medium-term growth Strategy ● Strengthe

  26. Slide 26: Look-back of Stage 3: Strategy/Organization

    Look-back of Stage 3: Strategy/Organization Strategy ⚫ Solution-based marketing activities Ratio of new drugs Projected: at least 50% Actual: 42.0% (FY2022) Shift to business based on the Launched FY2020: Lasvic IV 1 proposal of solutions and accelerate FY2021: Zymso the growth of new drug groups FY

  27. Slide 27: Look-back of Stage 3: Performance

    Look-back of Stage 3: Performance ■ Performance to realize sustainable growth Growth potential Net Sales CAGR at least 5% +1. 0% Operating profit before Profitability deduction of R&D expenses At least 20% of net sales 14. 2% <Negative Factors> COVID-19 pandemic caused: Markets of mainstay products

  28. Slide 28: Look-back of Stage 3: Our issue

    Look-back of Stage 3: Our issue Our Issue ● Continued the development of new drugs New drugs business ● Expansion of development pipeline (core business) ● Growth of new drugs ● Growth in GE business Helthcare-related ● Stable supply of products, stable procurement of API business ● Enhancement of t

  29. Slide 29: New long-term vision Vision 110 and Stage 1 plan

    New long-term vision “Vision 110”(FY2023-FY2032) and medium-term business plan “Vision 110 –Stage 1 –”(FY2023-FY2025) 29

  30. Slide 30: Long-term Vision

    Kyorin Group: Long-term vision “Vision 110” Long-term Vision Vision for 110 th anniversary [Our goal] A company that contributes broadly to people's health by comprehensively developing healthcare-related businesses, with a core focus on the new drug business, which continuously provides high-value

  31. Slide 31: Vision 110 - Stage 1

    Vision 110 -Stage 1 1. Strengthening drug discovery capability to create high-value new drugs that meet medical needs 2. Expansion of development pipeline through in-licensing 3. Maximization of the ratio of new drugs 4. Promoting healthcare-related businesses that have synergies with the new drugs

  32. Slide 32: Try for drug innovation through new drug discovery strategies

    Vision 110 -Stage 1 1. Strengthening drug discovery capability to create high-value new drugs that meet medical needs Try for drug innovation through new drug discovery strategies Development of new Strengthen research themes basic technology New targets Small molecule drugs Known targets Nucleic ac

  33. Slide 33: Expansion of development pipeline through in-licensing

    Vision 110 -Stage 1 2. Expansion of development pipeline through in-licensing Strengthen the foundation of new drug business by enhancement of in-licensing and alliance function and expansion of development pipeline Expand the scope of modality and therapeutic area Increase of Organizational reform

  34. Slide 34: Maximization of the ratio of new drugs

    Vision 110 -Stage 1 3. Maximization of the ratio of new drugs Products Aimed status Goal at FY2025 Sales (JPY billions) Beova® First-line treatment ⚫ No.1 in OAB market as Beova in FY2023 56.0 for OAB ⚫ 50% of patient’s share First-choice antibacterial ⚫ No.1 in oral new quinolone agent for elderly

  35. Slide 35: Promoting healthcare-related businesses with synergies

    Vision 110 -Stage 1 4. Promoting healthcare-related businesses that have synergies with the new drugs business Achieve sustainable growth in ⚫ Enhance an ability of drug development and accelerate growth business ⚫ Strive to stable supply by enhancement of manufacturing and SCM structure the generic

  36. Slide 36: Building a sustainable corporate foundation

    Vision 110 -Stage 1 5. Building a sustainable corporate foundation Improve cost competitiveness ⚫ Cost optimization along business environment ⚫ Human resource development for people leading Vision 110 ⚫ Revision of human resource system to improve career fulfillment Enhance human capital ⚫ Promote

  37. Slide 37: Performance target for FY2025

    Performance target for FY2025 ■ Performance targets (consolidated basis) Growth potential “Net sales” CAGR At least 2% Profitability Operating profit before deduction of R&D expenses At least 16% (operating profit + R&D expenses) Improve the company value according to meet high profitability by exec

  38. Slide 38: Capital policy and shareholder returns

    Performance target for FY2025 ■ Capital policy and shareholder returns Our capital policy is to improve capital efficiency through investment for growth and shareholder returns, while maintaining a sound financial base. Regarding shareholder returns, we will continue stable dividends, taking into ac

  39. Slide 39: Reform of management group structure and new initiatives

    FY2023 Management policy Reform of management group structure and new initiatives Reform of R&D Expand of systems development pipeline Maximize the expansion of sales Improve cost growth in new drugs competitiveness 39

  40. Slide 40: Disclaimer

    Disclaimer This material contains performance forecasts, goals and plans, and other forward-looking statements related to the Group. These statements are based on the judgment of the Group’s assumptions and outlooks based on the information and forecasts available at the time of preparation of this

  41. Slide 41: Kyorin ©)

    Kyorin ©)

KYORIN Pharmaceutical — FY2022 Earnings Presentation on 6ix